Bellevue Group Ag I Mab Transaction History

Bellevue Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$12.54 - $46.93 $1.82 Million - $6.8 Million	-144,957 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$45.28 - $74.5 $815,040 - $1.34 Million	-18,000 Reduced 11.05%	144,957 $6.87 Million
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $1.17 Million - $1.73 Million	-20,500 Reduced 11.17%	162,957 $11.8 Million
Q2 2021 Aug 12, 2021	SELL	$47.86 - $83.95 $717,900 - $1.26 Million	-15,000 Reduced 7.56%	183,457 $15.4 Million
Q1 2021 May 12, 2021	SELL	$44.38 - $63.97 $211,026 - $304,177	-4,755 Reduced 2.34%	198,457 $9.62 Million
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $4.55 Million - $6.52 Million	138,212 Added 212.63%	203,212 $9.58 Million
Q3 2020 Nov 16, 2020	BUY	$27.46 - $47.03 $1.78 Million - $3.06 Million	65,000 New	65,000 $3.06 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.1M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.